Monitor for IND filing and Phase 1 initiation for AKTX-101 in mid-2027, as well as any additional data from the Whitehawk collaboration. The $7.7M cash position provides a runway of roughly 12-18 months at current burn rates, making future financing a key catalyst.
Price Chart
Executive Summary
Akari Therapeutics reported Q2 2026 financial results, highlighting a net loss of $4.8M (vs. $1.9M in Q2 2025) as R&D expenses tripled to $2.1M to support IND-enabling work for lead ADC candidate AKTX-101. The company strengthened its balance sheet with ~$8.6M in gross proceeds from financing during the quarter, ending with $7.7M in cash. The pre-revenue biotech's stock will move on pipeline progress toward a mid-2027 Phase 1 trial start and the strategic collaboration with Whitehawk Therapeutics, not on the widening net loss.
Key Facts
- Net loss widened to $4.8M in Q2 2026 from $1.9M in Q2 2025, driven by R&D spend tripling to $2.1M.
- Cash balance improved to $7.7M as of June 30, 2026, from $5.2M at year-end 2025.
- Raised ~$8.6M in gross proceeds during Q2 via a $5.5M private placement and $3.1M in warrant exercises.
- Lead candidate AKTX-101 advancing through IND-enabling activities toward planned Phase 1 start in mid-2027.
- Entered a strategic research collaboration with Whitehawk Therapeutics to evaluate PH1 payload in dual-payload ADCs.
- Presented preclinical data at ASCO 2026 showing synergistic anti-tumor activity of PH1 payload with a KRAS inhibitor in pancreatic cancer models.
Financial Impact
Net loss of $4.8M in Q2 2026 vs $1.9M in Q2 2025; cash increased to $7.7M from $5.2M at year-end 2025.
Risk Factors
- Pre-revenue biotech with no approved products; requires additional capital to fund clinical development.
- AKTX-101 is still in IND-enabling stage; clinical failure or regulatory delays could destroy value.
- Cash runway limited to ~12-18 months at current burn rate; dilutive financing likely needed before data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037736 |
| Exhibit: ex99-1.htm | 0001493152-26-037736 |
| Document: 0001493152-26-037736-index-headers.html | 0001493152-26-037736 |
| Document: 0001493152-26-037736-index.html | 0001493152-26-037736 |
| Document: 0001493152-26-037736.txt | 0001493152-26-037736 |
| 8-K Data (Synthetic) | 0001493152-26-037736 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $7.63 (−12.50%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.63 (+1.19%) |
Jul 14, 2026 14w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.63 (+43.14%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.63 (−46.31%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.63 (+26.71%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.63 (−21.26%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.63 (−65.40%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.63 (+57.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers